OR WAIT null SECS
September 09, 2022
FDA backs the benefits of adopting continuous manufacturing, a strategy which has accelerated approval and launch timelines, and its Emerging Technology Program could be a helpful tool.
A fresh look at how industry benchmarks can help fortify new drug launches to overcome today’s new market-entry barriers and higher expectations.
Tracking the pandemic’s influence on brand awareness and prescribing efforts in light of decline in physician visits and fewer diagnoses—and what these dynamics, still unsettled post-pandemic, might mean for future launches.
August 24, 2022
Gaps remain in the pre-approval information process leave payers without all of the information they need to make the proper decisions.
August 10, 2022
The BCG Market Access Roundtable outlines the new and advanced access competencies required to enable functional operationalization and delivery of this critical role in biopharma—today a key strategic partner in achieving overall business goals.
Curative-type therapies offer great hope in further transforming treatments for cancer and other diseases, but addressing the economics of these products—and ultimately the cost-benefit equation—is daunting. What is being done to smooth the path for pricing and reimbursement?
August 03, 2022
Value-based price for access (VBPA) may increase access of specialty drugs for patients.
July 27, 2022
Using data visualizations to improve access to payers.
July 22, 2022
New MMIT research highlights payers’ continued hesitancy toward PDTs. Here’s what manufacturers need to know.
July 08, 2022
Reversing non-formulary status will usually require new data.
